These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35261888)

  • 1. A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma.
    Yan L; Lin J; Ke K; Wu Z; Huang J; Huang N; Yang W
    Transl Cancer Res; 2022 Jan; 11(1):99-112. PubMed ID: 35261888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Zhuang BW; Li W; Xie XH; Hu HT; Lu MD; Xie XY
    Jpn J Clin Oncol; 2019 Sep; 49(9):845-855. PubMed ID: 31063184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Long Y; Song X; Guan Y; Lan R; Huang Z; Li S; Zhang L
    J Gastroenterol Hepatol; 2023 Apr; 38(4):486-495. PubMed ID: 36516040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong S; Yu H; Wang H; Song J; Yan J
    Clin J Gastroenterol; 2023 Dec; 16(6):793-802. PubMed ID: 37740882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
    Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
    Liu BJ; Gao S; Zhu X; Guo JH; Zhang X; Chen H; Wang XD; Yang RJ
    World J Gastrointest Oncol; 2020 Jun; 12(6):663-676. PubMed ID: 32699581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis.
    Long GB; Xiao CW; Zhao XY; Zhang J; Li X
    Medicine (Baltimore); 2020 Jun; 99(26):e20745. PubMed ID: 32590750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
    Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
    J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis.
    Si T; Shao Q; Jassem W; Ma Y; Heaton N
    Int J Surg; 2024 Aug; ():. PubMed ID: 39093862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Peng P; Wen B; Chen R; Deng X
    Turk J Gastroenterol; 2023 Apr; 34(4):311-321. PubMed ID: 37089046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Kim HJ; Lee SH; Shim HJ; Bang HJ; Cho SH; Chung IJ; Hwang EC; Hwang JE; Bae WK
    Front Oncol; 2023; 13():1265240. PubMed ID: 37881486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study.
    Hiramine Y; Uto H; Imamura Y; Tabu K; Baba Y; Hiwaki T; Sho Y; Tahara K; Higashi H; Tamai T; Oketani M; Ido A; Tsubouchi H
    Exp Ther Med; 2011 May; 2(3):433-441. PubMed ID: 22977522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Ueshima K; Ogasawara S; Ikeda M; Yasui Y; Terashima T; Yamashita T; Obi S; Sato S; Aikata H; Ohmura T; Kuroda H; Ohki T; Nagashima K; Ooka Y; Takita M; Kurosaki M; Chayama K; Kaneko S; Izumi N; Kato N; Kudo M; Omata M
    Liver Cancer; 2020 Sep; 9(5):583-595. PubMed ID: 33083282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Ouyang G; Pan G; Xu H; Wu Y; Liu Z; Lu W; Yi B; Chen X
    J Clin Gastroenterol; 2020 Sep; 54(8):675-681. PubMed ID: 32569032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review.
    Zhang W; Ouyang D; Huang Z; Che X
    Front Oncol; 2023; 13():1085166. PubMed ID: 36776344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Hepatic Arterial Infusion Chemotherapy and Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Liu H; Qin X; Jiang H; Sun C; Wu M; Xu Z; Lu T; Ma X; Han Z
    J Gastrointestin Liver Dis; 2022 Sep; 31(3):336-343. PubMed ID: 36112704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis.
    Dai Y; Jiang H; Jiang H; Zhao S; Zeng X; Sun R; Zheng R
    Transl Oncol; 2021 Dec; 14(12):101238. PubMed ID: 34628285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.